600299 Bluestar Adisseo
- 10.12
- +0.19+1.91%
Bluestar Adisseo News
Andisu (600299): Methionine is growing better, production capacity continues to expand, consolidating leading position
Andisu (600299): Strong growth in methionine business, sharp increase in Q2 performance
Andisu (600299): High Q1 performance, continuous expansion of production capacity, steady development of the two pillars
Pacific released a research report on April 17 stating that it gave Andisu (600299.SH) an increase in holdings rating. The main reasons for the rating include: 1) market demand has recovered since the third quarter, and performance has gradually improved;
Andisu (600299): Gradual improvement in performance, expansion of production capacity to help growth
Andisu (600299): Performance in the second half of the year gradually improved, domestic and foreign production capacity layout strengthened competitive advantage
Andisu (600299): Short-term performance is under pressure, production capacity continues to expand, consolidates leading position
Andisu (600299) 2023 performance pre-reduction announcement comment: 23-year results are under downward pressure, and the methionine boom has bottomed out and picked up
Andisu (600299): Short-term performance under pressure, specialty products business brings growth
Andisu (600299): Performance is under pressure, production capacity continues to increase, consolidating leading position
Andisu (600299) review of the 2023 semi-annual report: Methionine and vitamin boom declined 23H1 performance, continued to expand methionine production capacity under pressure
Andisu (600299) 2022 Annual Report Review: Return to Mother's Net Profit in '22 fell 15.29% year-on-year, and I'm optimistic that the start of the Nanjing Phase II project will bring high growth
Andy Su (600299): Return to Mother's net profit fell 15.29% year-on-year in '22, and I'm optimistic that the start of the Nanjing Phase II project will bring high growth
Andisu (600299): Rising costs and performance put pressure on the second pillar for steady development
Andisu (600299): Higher costs, performance pressure, production capacity release can be expected in the future
Andisu (600299): The second phase of production consolidates the position of endogenous and external extension to promote development
Andisu (600299): Cost increases are hard to hide, and there is room for both pillars of resilience to work together
Andy Su (600299): continuous improvement of methionine production capacity two-pillar strategy to drive long-term development
Andy Su (600299): methionine sales increased significantly in the first half of 22 years.
Andisu (600299): Global leader growth is imminent, and performance elasticity is worth looking forward to
Analysis
Price Target
No Data
No Data